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Analysis of Chlamydia
trachomatis serovar distribution
changes in the Netherlands
(1986–2002)
Up to 19 different Chlamydia trachomatis (CT)
serovars which are pathogenic predominantly
for the urogenital tract and numerous CT
variants have been identified.1 2 An increas-
ing number of isolates are typed worldwide
and provide a wealth of information on the
epidemiology of CT infections, a sexually
transmitted disease (STD) for which screen-
ing has been proposed.3–5 Recent studies have
demonstrated an association between CT
serovar G and squamous cell carcinoma.6 A
possible shift in the serovar distribution over
time in a region or country could reveal
information on changes in the epidemiology
of CT infections and could potentially have
clinical implications.
We therefore determined the CT serovar
distribution in a large STD population in
Amsterdam in 2000–2 and compared it
together with all published serovar distribu-
tions since 1986 in the Netherlands to assess
if serovar distribution shifts over time
occurred.
Of people attending the STD outpatient
clinic in Amsterdam from 2000–2, those
found CT positive (n = 407) by LCx (Abbott
Laboratories, Chicago, IL, USA) were geno-
typed as described previously.1 This is the
largest STD population typed to date in The
Netherlands. The following serovar distribu-
tion was found: B = 1%; D = 12%; Da = 0.2%;
D- = 1%: E = 33%; F = 23%; G = 4%; Ga =
5%; H = 8%; I = 6%; Ia = 1%; J = 3%; K = 2%.
Literature searches identified eight serovar
distribution studies in the Netherlands, of
which the first was performed in 1986. With
the inclusion of the present study, 2204
serovars were available for analyses. In the
serovar distributions comparison, we (1) did
not distinguish between male and female
participants, (2) did not distinguish between
serovar distributions based on serotyping or
genotyping techniques, (3) excluded serovars
B/Ba because of the low numbers, (4)
excluded double infections, (5) excluded
variants, and (6) classified CT serovars in
the three phylogenetically based serogroups:
the B group (serovars D, Da, D-, E), the
intermediate serogroup (serovars F, G, Ga),
and the C group (serovars I, Ia, J, Jv, and K).
Results are shown in figure 1. In general,
no statistical significant serovar distribution
trends in time were observed between 1986
and 2002 when all studies were taken
together. Of the nine studies, 1 and 6
represent serovar distributions from STD
populations in Rotterdam and show no
significant changes in general or over time
(mean: C group: 30%; Int group: 21%; B
group: 49%). Studies 2, 3, 4, and 9 represent
serovar distributions from STD populations in
Amsterdam and show no significant changes
(mean: C group: 20%; Int group: 31%; B
group: 49%). Studies 5, 7, and 8 represent
serovar distributions from mixed sympto-
matic and asymptomatic infected people (5
and 7) and asymptomatically infected popu-
lations in Amsterdam. They show no sig-
nificant changes in general, over time, or
compared to the Amsterdam STD based
serovar distribution (C group: 17%; Int group:
30%; B group: 53%).
However, when the two geographically
derived serovar distributions were compared
to each other, (1) serogroup C was found
more frequently in Rotterdam: 30 v 19%
(p,0.0001; OR 1.8 (95% CI: 1.4 to 2.3)), the
most prominent serovar difference was sero-
var K (10.6 v 3.2%, p,0.0001; OR 3.6 (95% CI
2.4 to 5.3)); (2) the intermediate serogroup
was found less frequently in Rotterdam: 21 v
31% (p = 0.0002; OR 1.6 (95% CI: 1.2 to 2.0)),
the most prominent serovar difference was
serovar F (15 v 22%, p = 0.0018; OR 1.6 (95%
CI: 1.2 to 2.1)), and serogroup B was stable
(49% v 50%).
In conclusion, no changes in serovar
distribution differences were found over time
in the Netherlands in general or within the
two different geographic areas. However, the
Rotterdam population differed significantly
from the Amsterdam populations in having a
larger incidence of C group serovars and a
lower incidence of the intermediate group
serovars, albeit an identical B group serovar
distribution. The findings could be the result
of different ethnic compositions of the
studied cohorts or other confounding factors
between Rotterdam and Amsterdam, a sub-
ject that warrants further study.
Figure 1 Serovar distribution studies in the Netherlands from 1986 to 2002. The time of cohort
collections is shown since the year of publication can be different from the year of cohort collection.
Differences in serovar distributions in time were analysed. Each study is indicated by first author,
year of publication, and number of isolates included: 1, Wagenvoort, 1998, n = 190; 2, vd Laar,
1996, n = 372; 3, Morre´, 1998, n = 90; 4, Ossewaarde, 1994, n = 289; 5, Lan, 1995, n = 51;
6, v Duynhoven, 1998, n = 305; 7, Morre´, 2000, n = 426; Morre´, 1998, n = 74; 9, Spaargaren,
this study, n = 407. C = serogroup C (serovars H, I, Ia/I9, J, Jv, K); Int = intermediate serogroup
(serovars F, G, Ga); B = serogroup B (serovars D, Da, D-, E).
Key messages
N No statistically significant serovar distri-
bution shifts were observed between
1986 and 2002 in the Netherlands
N The type of cohort did not influence the
analyses: STD based, asymptomatically
screenings based, mixed cohorts
N Geographical serovar distribution differ-
ences were observed between Rotterdam
and Amsterdam but these were stable in
time:
– serogroup C was found more fre-
quently in Rotterdam: 30 v 20%,
p,0.0001, most prominent serovar
difference was serovar K (10.6 v
3.2%, p,0.0001)
– the Intermediate serogroup was
found less frequently: 21 v 31%,
p = 0.0002, most prominent serovar
difference was serovar F (15 v 22%,
p = 0.0018)
– serogroup B was stable (49% v 50%)
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Surveillance of sexually
transmitted infections in primary
care
Surveillance for sexually transmitted infec-
tions must respond to increases in the
provision of sexual health services outside
genitourinary clinics. Simms et al1 propose
repeated panel surveys in general practices to
improve surveillance in primary care, monitor
changes in prevalence over time, and address
the current lack of behavioural data.
There are some limitations to this
approach. Firstly, prevalence surveys will
not measure actual diagnostic activity in
primary care and other clinical settings. This
is essential for determining whether propo-
sals from the National Strategy for Sexual
Health2 are being implemented effectively.
Secondly, periodic surveys in different areas
could not readily identify outbreaks. In the
Bristol area, for example, most cases in an
ongoing outbreak of sexually transmitted
hepatitis B infection have presented to gen-
eral practitioners.3 Although genitourinary
medicine clinics are the main setting for
detecting outbreaks their impact in primary
care should be monitored. Thirdly, the
validity of panel surveys will depend on a
high response rate and postal invitations
often have low uptake.4
A single system cannot fulfil all the
requirements for infectious disease surveil-
lance. Laboratory reporting remains incom-
plete5 and denominator data need to be
available for infections other than chlamydia
for appropriate interpretation of time trends.
Routine collection of data on laboratory
diagnosed sexually transmitted infections
from all clinical settings and linkage to
demographic data could complement current
proposals.
The Avon Surveillance System for Sexually
Transmitted Infections (ASSIST) integrates
person based genitourinary clinic and labora-
tory data to provide information for action at
local level and to inform national initiatives.6
Data on positive and negative tests for
laboratory diagnosed infections taken in any
clinical setting are collected from the Health
Protection Agency and trust laboratories.
Postcode information for geographical map-
ping and small area analysis is obtained by
matching pseudoanonymised data with GP
registration databases. These data are also
matched to disaggregate data from genitour-
inary and Brook clinics to identify duplicate
tests and obtain geographic data for infec-
tions diagnosed in these settings.
ASSIST project data can be used to
estimate the population burden of diagnosed
infections and explore associations with
demographic and socioeconomic characteris-
tics over time. Automating regular data
downloads and reporting will improve the
timeliness of data collection to facilitate
identification and monitoring of outbreaks.
The wide coverage of the system can guide
local service development and clinical prac-
tice and monitor the impact of the Sexual
Health Strategy. For example, in 2001 half of
all chlamydia tests and 44% of positive results
came from GP, family planning, or Brook
clinics. Nearly two thirds (62%) of those
tested in general practice were over 25 years
old in whom the positivity rate was 4%
compared with 11% for under 25 year olds.
We propose that, while behavioural data
obtained from panel surveys in primary care
provide depth, sentinel surveillance of labora-
tory diagnosed infections in all clinical set-
tings provides breadth, and both are needed
for effective surveillance.
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Comparison of the serological
response to treatment of early
syphilis in HIV positive versus HIV
negative individuals
The effectiveness of treatment for syphilis is
evaluated by demonstrating declining titres
of the non-treponemal antibody tests—for
example, the rapid plasma reagin (RPR). The
serological response in HIV co-infected indi-
viduals has been the subject of debate, with
some studies reporting a similar serological
response1 2 and others a delayed response in
HIV positive patients.3 4
A resurgence of infectious syphilis has
occurred in Manchester, United Kingdom,
in recent years.5 From January 1999 to
August 2002, 379 cases of early syphilis were
152 PostScript
www.stijournal.com
